Test Background MMF is metabolised to mycophenylic acid, which has a more selective mode of action than azathioprine. It is licensed for the prophylaxis of acute rejection in renal or cardiac transplantation when used in combination with ciclosporin and corticosteroids.
Clinical Indications Therapeutic drug monitoring for patients undergoing combination immunosuppression therapy following (typically kidney/heart) transplantation.
Reference Range See report
Sample Required EDTA (lavender top)
Sample Volume 2 mL (Timed see below)
Within 5 days from receipt of sample into the Leslie Brent Laboratory
The sample should be taken just before the subsequent dose (trough level) and at a constant interval; 12h
Test performed 3 times a week
Not currently performed in house; this is a referred test. Please send specimens directly to the Leslie Brent Laboratory, West London Renal and Transplant Centre, Hammersmith Hospital 020 331 36637 Clinical Biochemistry will forward any specimens received to the Leslie Brent Laboratory.